Abstract:Autoimmune bullous skin disorders are rare but meaningful chronic inflammatory diseases, many of which had a poor or devastating prognosis prior to the advent of immunosuppressive drugs such as systemic corticosteroids, which down-regulate the immune pathogenesis in these disorders. Glucocorticoids and adjuvant immunosuppressive drugs have been of major benefit for the fast control of most of these disorders, but their long-term use is limited by major side effects such as blood cytopenia, osteoporosis, diabetes mellitus, hypertension, and gastrointestinal ulcers. In recent years, major efforts were made to identify key elements in the pathogenesis of autoimmune bullous disorders, leading to the identification of their autoantigens, which are mainly located in desmosomes (pemphigus) and the basement membrane zone (pemphigoids). In the majority of cases, immunoglobulin G, and to a lesser extent, immunoglobulin A autoantibodies directed against distinct cutaneous adhesion molecules are directly responsible for the loss of cell-cell and cell-basement membrane adhesion, which is clinically related to the formation of blisters and/or erosions of the skin and mucous membranes. We describe and discuss novel therapeutic strategies that directly interfere with the production and regulation of pathogenic autoantibodies (rituximab), their catabolism (intravenous immunoglobulins), and their presence in the circulation and extravascular tissues such as the skin (immunoadsorption), leading to a significant amelioration of disease. Moreover, we show that these novel therapies have pleiotropic effects on various proinflammatory cells and cytokines. Recent studies in bullous pemphigoid suggest that targeting of immunoglobulin E autoantibodies (omalizumab) may be also beneficial. In summary, the introduction of targeted therapies in pemphigus and pemphigoid holds major promise because of the high efficacy and fewer side effects compared with conventional global immunosuppressive therapy.

Immune-enhancing agents in autoimmune skin diseases – A review

Non‐biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

Emerging drugs for the treatment of vitiligo

Autoimmunity in vitiligo: Therapeutic implications and opportunities

Updates on the Management of Autoimmune Bullous Diseases

From traditional to targeted: the changing trajectory of therapies in dermatomyositis

Immunopathology and Immunotherapy of Inflammatory Skin Diseases

Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis

Emerging therapies and innovations in vitiligo management: a comprehensive review

The skin in autoimmune diseases-Unmet needs

The attentive focus on T cell‐mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo

Immune-mediated inflammatory disease therapeutics: past, present and future

Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review

Vitiligo: advances in pathophysiology research and treatment development

Targeted Therapies for Autoimmune Bullous Diseases: Current Status

The role of intravenous immunoglobulin in autoimmune diseases with dermatological implications

Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

Autoimmune blistering diseases: promising agents in clinical trials

Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases